Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-94.83%
operating margin TTM
-77.02%
revenue TTM
111.47 Million
revenue per share TTM
2.29$
valuation ratios | |
|---|---|
| pe ratio | -14.51 |
| peg ratio | -1.18 |
| price to book ratio | -16.11 |
| price to sales ratio | 13.84 |
| enterprise value multiple | -16.05 |
| price fair value | -16.11 |
profitability ratios | |
|---|---|
| gross profit margin | 89.85% |
| operating profit margin | -77.02% |
| pretax profit margin | -98.45% |
| net profit margin | -94.83% |
| return on assets | -52.51% |
| return on equity | 121.52% |
| return on capital employed | -53.29% |
liquidity ratios | |
|---|---|
| current ratio | 4.69 |
| quick ratio | 4.28 |
| cash ratio | 2.20 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 535.65 |
| operating cycle | 679.61 |
| days of payables outstanding | 440.61 |
| cash conversion cycle | 239.00 |
| receivables turnover | 2.54 |
| payables turnover | 0.83 |
| inventory turnover | 0.68 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.78 |
| debt equity ratio | -1.59 |
| long term debt to capitalization | 2.90 |
| total debt to capitalization | 2.71 |
| interest coverage | -2.81 |
| cash flow to debt ratio | -0.84 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.31 |
| cash per share | 2.82 |
| operating cash flow per share | -3.30 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.84 |
| short term coverage ratios | -86.50 |
| capital expenditure coverage ratio | -554.30 |
Frequently Asked Questions
When was the last time UroGen Pharma Ltd. (NASDAQ:URGN) reported earnings?
UroGen Pharma Ltd. (URGN) published its most recent earnings results on 06-05-2026.
What is UroGen Pharma Ltd.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. UroGen Pharma Ltd. (NASDAQ:URGN)'s trailing twelve months ROE is 121.52%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. UroGen Pharma Ltd. (URGN) currently has a ROA of -52.51%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did URGN's net profit margin stand at?
URGN reported a profit margin of -94.83% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is URGN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.69 in the most recent quarter. The quick ratio stood at 4.28, with a Debt/Eq ratio of -1.59.